Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Laura Z. Vanags; Joanne T.M. Tan; Keyvan K. Galougahi; Andreas Schaefer; Steven G. Wise; Andrew Murphy; Ziad A. Ali; Christina A. Bursill

doi:10.1016/j.jacbts.2017.11.006

Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Laura Z. Vanags
, Joanne T.M. Tan
, Keyvan K. Galougahi
, Andreas Schaefer
, Steven G. Wise
, Andrew Murphy
, Ziad A. Ali
, Christina A. Bursill

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.

Original language	English
Pages (from-to)	200-209
Number of pages	10
Journal	JACC: Basic to Translational Science
Volume	3
Issue number	2
DOIs	https://doi.org/10.1016/j.jacbts.2017.11.006
Publication status	Published or Issued - Apr 2018
Externally published	Yes

Keywords

apolipoprotein A-I
endothelialization
neointimal hyperplasia
platelet activation
stent biocompatibility

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacbts.2017.11.006

Cite this

@article{1ab1b199874348058f906984118af74f,

title = "Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype",

abstract = "Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.",

keywords = "apolipoprotein A-I, endothelialization, neointimal hyperplasia, platelet activation, stent biocompatibility",

author = "Vanags, \{Laura Z.\} and Tan, \{Joanne T.M.\} and Galougahi, \{Keyvan K.\} and Andreas Schaefer and Wise, \{Steven G.\} and Andrew Murphy and Ali, \{Ziad A.\} and Bursill, \{Christina A.\}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = apr,

doi = "10.1016/j.jacbts.2017.11.006",

language = "English",

volume = "3",

pages = "200--209",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

AU - Vanags, Laura Z.

AU - Tan, Joanne T.M.

AU - Galougahi, Keyvan K.

AU - Schaefer, Andreas

AU - Wise, Steven G.

AU - Murphy, Andrew

AU - Ali, Ziad A.

AU - Bursill, Christina A.

PY - 2018/4

Y1 - 2018/4

N2 - Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.

AB - Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.

KW - apolipoprotein A-I

KW - endothelialization

KW - neointimal hyperplasia

KW - platelet activation

KW - stent biocompatibility

UR - https://www.scopus.com/pages/publications/85045580074

U2 - 10.1016/j.jacbts.2017.11.006

DO - 10.1016/j.jacbts.2017.11.006

M3 - Article

AN - SCOPUS:85045580074

SN - 2452-302X

VL - 3

SP - 200

EP - 209

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 2

ER -

Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this